Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress

Jung Lim Kim, Dae Hee Lee, Soyeon Jeong, Bo Ram Kim, Yoo Jin Na, Seong Hye Park, Min Jee Jo, Yoon A. Jeong, Sang Cheul Oh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Imatinib is a powerful tyrosine kinase inhibitor that specifcally targets BCR-ABL, c-KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria-mediated a p opt o sis of ga st r ic ca nc er cel ls by i nvolvi ng end opla sm ic r et ic-ulum (ER) stress-associated activation of c-Jun NH2-terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time- and dose-dependent manner. Cell cycle analysis revealed that imatinib-treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib-treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress-associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5-Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress-associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet-derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer.

Original languageEnglish
Pages (from-to)1616-1626
Number of pages11
JournalOncology Reports
Volume41
Issue number3
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Endoplasmic Reticulum Stress
Stomach Neoplasms
Apoptosis
JNK Mitogen-Activated Protein Kinases
irinotecan
Cell Cycle
Imatinib Mesylate
Transcription Factor CHOP
Platelet-Derived Growth Factor Receptors
Gastrointestinal Stromal Tumors
G2 Phase
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination Drug Therapy
Cell Division
Protein-Tyrosine Kinases
Reactive Oxygen Species
Cell Survival
Mitochondria
Transcription Factors

Keywords

  • C-Jun NH-terminal kinase
  • Endoplasmic reticulum stress
  • Gastric cancer
  • Imatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. / Kim, Jung Lim; Lee, Dae Hee; Jeong, Soyeon; Kim, Bo Ram; Na, Yoo Jin; Park, Seong Hye; Jo, Min Jee; Jeong, Yoon A.; Oh, Sang Cheul.

In: Oncology Reports, Vol. 41, No. 3, 01.03.2019, p. 1616-1626.

Research output: Contribution to journalArticle

Kim, JL, Lee, DH, Jeong, S, Kim, BR, Na, YJ, Park, SH, Jo, MJ, Jeong, YA & Oh, SC 2019, 'Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress', Oncology Reports, vol. 41, no. 3, pp. 1616-1626. https://doi.org/10.3892/or.2018.6945
Kim, Jung Lim ; Lee, Dae Hee ; Jeong, Soyeon ; Kim, Bo Ram ; Na, Yoo Jin ; Park, Seong Hye ; Jo, Min Jee ; Jeong, Yoon A. ; Oh, Sang Cheul. / Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. In: Oncology Reports. 2019 ; Vol. 41, No. 3. pp. 1616-1626.
@article{d473c8a7fcb448e88f914c1e90c98750,
title = "Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress",
abstract = "Imatinib is a powerful tyrosine kinase inhibitor that specifcally targets BCR-ABL, c-KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria-mediated a p opt o sis of ga st r ic ca nc er cel ls by i nvolvi ng end opla sm ic r et ic-ulum (ER) stress-associated activation of c-Jun NH2-terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time- and dose-dependent manner. Cell cycle analysis revealed that imatinib-treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib-treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress-associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5-Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress-associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet-derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer.",
keywords = "C-Jun NH-terminal kinase, Endoplasmic reticulum stress, Gastric cancer, Imatinib",
author = "Kim, {Jung Lim} and Lee, {Dae Hee} and Soyeon Jeong and Kim, {Bo Ram} and Na, {Yoo Jin} and Park, {Seong Hye} and Jo, {Min Jee} and Jeong, {Yoon A.} and Oh, {Sang Cheul}",
year = "2019",
month = "3",
day = "1",
doi = "10.3892/or.2018.6945",
language = "English",
volume = "41",
pages = "1616--1626",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress

AU - Kim, Jung Lim

AU - Lee, Dae Hee

AU - Jeong, Soyeon

AU - Kim, Bo Ram

AU - Na, Yoo Jin

AU - Park, Seong Hye

AU - Jo, Min Jee

AU - Jeong, Yoon A.

AU - Oh, Sang Cheul

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Imatinib is a powerful tyrosine kinase inhibitor that specifcally targets BCR-ABL, c-KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria-mediated a p opt o sis of ga st r ic ca nc er cel ls by i nvolvi ng end opla sm ic r et ic-ulum (ER) stress-associated activation of c-Jun NH2-terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time- and dose-dependent manner. Cell cycle analysis revealed that imatinib-treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib-treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress-associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5-Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress-associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet-derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer.

AB - Imatinib is a powerful tyrosine kinase inhibitor that specifcally targets BCR-ABL, c-KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria-mediated a p opt o sis of ga st r ic ca nc er cel ls by i nvolvi ng end opla sm ic r et ic-ulum (ER) stress-associated activation of c-Jun NH2-terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time- and dose-dependent manner. Cell cycle analysis revealed that imatinib-treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib-treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress-associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5-Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress-associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet-derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer.

KW - C-Jun NH-terminal kinase

KW - Endoplasmic reticulum stress

KW - Gastric cancer

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=85060828526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060828526&partnerID=8YFLogxK

U2 - 10.3892/or.2018.6945

DO - 10.3892/or.2018.6945

M3 - Article

VL - 41

SP - 1616

EP - 1626

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -